Ponsegromab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | GDF-15 |
| Clinical data | |
| Other names | PF-06946860 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia.[1][2][3][4][5]
In September 2024, Pfizer disclosed that ponsegromab led to significant body weight increases in patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer in a phase 2 clinical trial.[6]
